PROSPECTS OF THE USE OF RADIOPROTECTORS TO OVERCOME MITOCHONDRIAL DYSFUNCTION OF HEALTHY CELLS SURROUNDING THE IRRADIATED TUMOR
DOI:
https://doi.org/10.15407/oncology.2023.01.074Keywords:
therapeutic irradiation, radiation complications, mitochondrial dysfunction, amifostine, melatonin.Abstract
Radiation-induced changes in normal cells, including their mitochondria, from around the tumor can lead to the development of remote complications that negatively affect the effectiveness of radiation therapy. This determines the search for radioprotectors capable of overcoming the membrane barrier of mitochondria and suppressing their acquired dysfunction for selective protection of healthy tissues. The use of amifostine and melatonin radiomitigators, whose action is characterized by low toxicity, the ability to overcome acquired mitochondrial dysfunction, and unimpeded penetration into the mitochondria of various types of cells, is recognized as a reliable and effective means of protection. The appointment of the specified drugs to accompany radiation therapy of oncological patients is substantiated and recommended.
References
Domina EA, Makovetska LI, Druzhyna MO. Relevant biochemical induces of blood radiosensitivity in gynecological cancer patients. Problems Radiat Med Radiobiol 2022; 27: 216–33.
Clutton SM, Townsend KM, Walker C, et al. Radiation-induced genomic instability and persisting oxidative stress in primary bone marrow cultured. Carcinogenesis 1996; 17 (8): 1633–39. doi: 10.1093/carcin/17.8.1633.
Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat Rev Cancer 2006; 6 (9): 702–13. doi: 10.1038/nrc1950.
Brown TA. Genomes. 2nd edition. Chapter 1. The Human Genome. Oxford: Wiley-Liss; 2002. PMID: 20821850.
Bazyka DA, Lytvynenko OO, Lytvynenko OO. Classification of medical equipment for anti-radiation protection. Problems Radiat Med Radiobiol 2022; 27: 84–106.
Domina E, Philchenkov A, Dubrovska A. Individual response to ionizing radiation and personalized radiotherapy. Crit Rev Oncog 2018; 23 (1-2): 69–92. doi: 10.1615/CritRevOncog.2018026308
Athanassiou E, Antonadou D, Coliarakis N, et al. Protective effect of Amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys 2003; 56 (4): 1154–60. doi: 10.1016/s0360-3016(03)00187-1.
Domina E. Expediency on using radiomitigators in radiation therapy of cancer patients. Journal of science Lyon France 2020; 1 (10): 7–11.
King M, Joseph S, Albert A, et al. Use of amifostine for cytoprotection during radiation therapy: a review. Oncology 2020; 98 (2): 61–80. doi: 10.1159/000502979.
Capizzi RL. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol). Eur J Cancer 1996; 32A (4): 5–16.
Zielonka J. Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev 2017; 117 (15): 10043–120.
Galano A. Melatonin: a versatile protector against oxidative DNA damage. Molecules 2018; 23 (530): 1–36.
Farhood B. Melatonin and cancer: From the promotion of genomic stability to use in cancer treatment. J Cell Physiol 2019; 234 (5): 5613–27. doi: 10.1002/jcp.27391.
Tarocco A. Melatonin as a master regulator of cell death and inflammation: molecular mechanisms and clinical implications for newborn care. Cell Death Dis 2019; 10 (4): 317. doi:10.1038/s4141.
